NASDAQ · OPRX

OptimizeRx Corporation

$6.38 +$0.14 (+2.24%) 1D Market open

Key Metrics

$117.09M
Market cap
17.13×
P/E · TTM
$107.35M
Revenue · TTM
$6.84M
Net income
EPS · TTM $0.37
Dividend yield
Free cash flow $14.33M
Beta · 1Y 2.17
EBITDA · TTM
Gross margin 56.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 23
    From its Feb 4 high, the share price fell 59%.

    Peak close $11.02 on Feb 4; trough close $4.54 on Jun 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -59%
  • May 13
    The stock moved -22.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 13
  • Mar 12
    The stock moved -11.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$117.09M
Enterprise value$120.27M
Shares outstanding18.8M
52-wk range$4.54 – $22.25
Avg volume · 20D252.9K
Net cash −$3.17M
Book value / share$7.02
IndustryServices-Business Services, Nec
ExchangeNASDAQ
About OptimizeRx Corporation
IPO dateOct 22, 1996
Employees105

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E17.13
P/S1.09
P/FCF8.17
EV/EBITDA
EV/Sales1.12
Graham №$7.64

Profitability

Gross 56.1%
Operating 8.9%
Net 6.4%
FCF 13.4%
ROE / ROIC 5.5% · 5.1%

Financial Health

Current ratio5.37
Quick ratio
Debt / equity0.18
Debt / EBITDA
Net cash −$3.17M
Working capital$45.71M

Cash Flow · TTM

Operating CF $14.38M
Capex −$52.00K
Free cash flow $14.33M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

8 / 9
Strong fundamentals · 8 of 9 signals passing

Altman Z-Score

2.4
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$7.64 vs $6.38
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings